Bradley Justus Recognized in Bloomberg Law’s “They’ve Got Next: The 40 Under 40”
August 13, 2025
Axinn is pleased to announce that Partner Bradley Justus has been honored in Bloomberg Law’s prestigious “They’ve Got Next: The 40 Under 40” list, celebrating top legal professionals age 40 and under.
Bradley’s practice focuses on high-stakes antitrust matters. His numerous high-profile representations include serving as counsel in headline-making litigations concerning Google’s ad technology business against the U.S. Department of Justice (DOJ), state attorneys general, private class plaintiffs, the Daily Mail, and Gannett, as well as securing antitrust clearance for Dow Chemical’s $130 billion merger with DuPont—one of the largest and most complex merger reviews in history. He has also helped clients prevail in challenging post-patent-loss antitrust cases and has resolved significant disputes for Tyson Foods and others.
In his Bloomberg profile, Bradley reflected on the lessons learned early in his career about empathy, teamwork, and resilience, values that continue to guide his leadership today. He emphasized his commitment to mentoring colleagues, fostering Axinn’s collaborative culture, and helping lawyers thrive both professionally and personally.
Click here to read Bradley's full profile.
About Axinn
Incisive. Inclusive. Invested. Inquisitive. We’re Axinn. Focusing on antitrust, intellectual property, and litigation, we make it our mission to understand your business so we can anticipate every move. Acting with precision and conviction, we protect and accelerate your business growth, always thinking ahead.
To subscribe to our publications, click here.
Featured Insights
Featured Insights
ABA White Collar Crime Institute 2026
Speaking Engagement
GCR Live Cartels: 2026
Speaking Engagement
Antitrust
Noerr Competition Day 2026
Speaking Engagement
Antitrust
Consumer Brands CPG Legal Forum 2026
Speaking Engagement
NBA CLS 39th Annual Corporate Counsel Conference
Sponsorship
Antitrust
University of Pennsylvania Journal of Business Law Annual Symposium 2026
Speaking Engagement
Antitrust
No More Needles in Haystacks: Congress Requires FDA to Explain Q1/Q2 Sameness
Axinn Viewpoints
Intellectual Property
Oliver Twisted Again: After FDA's Court Losses, Congress Approves FDA's Standards on Orphan Drug Exclusivity
Axinn Viewpoints
Intellectual Property
2025 Healthcare Antitrust Enforcement Wrap Up
Axinn Viewpoints
Antitrust
Here We Go Again: Third Round of Inflation Reduction Act Drugs Listed
Axinn Viewpoints
Intellectual Property
